734 related articles for article (PubMed ID: 32726528)
1. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
2. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
4. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN;
N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500
[TBL] [Abstract][Full Text] [Related]
5. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.
Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF;
N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529
[TBL] [Abstract][Full Text] [Related]
6. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Mallah N; Ares-Gómez S; Pardo-Seco J; Malvar-Pintos A; Santiago-Pérez MI; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; González-Pérez JM; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
Hum Vaccin Immunother; 2024 Dec; 20(1):2348135. PubMed ID: 38738683
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Bergeron HC; Tripp RA
Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
[TBL] [Abstract][Full Text] [Related]
8. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
Domachowske JB; Khan AA; Esser MT; Jensen K; Takas T; Villafana T; Dubovsky F; Griffin MP
Pediatr Infect Dis J; 2018 Sep; 37(9):886-892. PubMed ID: 29373476
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
12. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
Dagan R; Hammitt LL; Seoane Nuñez B; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Chang Y; Currie A; Grenham A; Shroff M; Takas T; Mankad VS; Leach A; Villafana T
J Pediatric Infect Dis Soc; 2024 Feb; 13(2):144-147. PubMed ID: 38219024
[TBL] [Abstract][Full Text] [Related]
13. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
[TBL] [Abstract][Full Text] [Related]
14. Nirsevimab: First Approval.
Keam SJ
Drugs; 2023 Feb; 83(2):181-187. PubMed ID: 36577878
[TBL] [Abstract][Full Text] [Related]
15. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
Kampmann B; Madhi SA; Munjal I; Simões EAF; Pahud BA; Llapur C; Baker J; Pérez Marc G; Radley D; Shittu E; Glanternik J; Snaggs H; Baber J; Zachariah P; Barnabas SL; Fausett M; Adam T; Perreras N; Van Houten MA; Kantele A; Huang LM; Bont LJ; Otsuki T; Vargas SL; Gullam J; Tapiero B; Stein RT; Polack FP; Zar HJ; Staerke NB; Duron Padilla M; Richmond PC; Koury K; Schneider K; Kalinina EV; Cooper D; Jansen KU; Anderson AS; Swanson KA; Gruber WC; Gurtman A;
N Engl J Med; 2023 Apr; 388(16):1451-1464. PubMed ID: 37018474
[TBL] [Abstract][Full Text] [Related]
16. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
Cieslak CM
Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
[TBL] [Abstract][Full Text] [Related]
17. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
[TBL] [Abstract][Full Text] [Related]
18. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
[TBL] [Abstract][Full Text] [Related]
19. Balanced on the Biggest Wave: Nirsevimab for Newborns.
McPherson C; Lockowitz CR; Newland JG
Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
